Regentys Overview
- Year Founded
-
2013

- Status
-
Acquired/Merged
- Employees
-
4

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$15M
Regentys General Information
Description
Developer of tissue-engineered therapy designed to treat gastrointestinal disorders. The company develops a porcine-derived biological material that acts as a catalyst to stimulate the body to grow new, healthy tissue in place of diseased or damaged tissue and it mainly focuses on treatment for Inflammatory Bowel Disease, enabling patients to recover rare diseases.
Contact Information
Website
www.regentys.com(Operating Subsidiary)
Corporate Office
- 6135 Northwest 167th Street
- Suite E15
- Miami Lakes, FL 33015
- United States
Corporate Office
- 6135 Northwest 167th Street
- Suite E15
- Miami Lakes, FL 33015
- United States
Regentys Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Merger/Acquisition | 07-Jan-2019 | $15M | Completed | Clinical Trials - General | ||
3. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
2. Early Stage VC (Series A) | 07-Nov-2016 | $1.45M | $1.7M | Completed | Clinical Trials - General | |
1. Accelerator/Incubator | 31-Oct-2014 | $250K | $250K | Completed | Clinical Trials - General |
Regentys Patents
Regentys Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3500193-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Inactive | 19-Aug-2016 | ||
US-20190184060-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Inactive | 19-Aug-2016 | ||
CA-3034251-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Inactive | 19-Aug-2016 | ||
EP-3500193-A4 | Extracellular matrix for tissue reconstruction of mucosal tissue | Inactive | 19-Aug-2016 | ||
AU-2017313207-A1 | Extracellular matrix for tissue reconstruction of mucosal tissue | Inactive | 19-Aug-2016 | A61L27/3633 |
Regentys Signals
Regentys Former Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
43North | Accelerator/Incubator | Minority | ||
University of Pittsburgh Innovation Institute | Accelerator/Incubator |
Regentys FAQs
-
When was Regentys founded?
Regentys was founded in 2013.
-
Where is Regentys headquartered?
Regentys is headquartered in Miami Lakes, FL.
-
What is the size of Regentys?
Regentys has 4 total employees.
-
What industry is Regentys in?
Regentys’s primary industry is Drug Discovery.
-
Is Regentys a private or public company?
Regentys is a Private company.
-
What is the current valuation of Regentys?
The current valuation of Regentys is
. -
What is Regentys’s current revenue?
The current revenue for Regentys is
. -
How much funding has Regentys raised over time?
Regentys has raised $1.7M.
-
Who are Regentys’s investors?
43North and University of Pittsburgh Innovation Institute have invested in Regentys.
-
When was Regentys acquired?
Regentys was acquired on 07-Jan-2019.
-
Who acquired Regentys?
Regentys was acquired by Generex Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »